已收盤 11-20 16:00:00 美东时间
-0.005
-0.33%
Plenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against cancers expressing antigens of interest while overcoming inhibitory signals that constrain anti-tumo...
11-20 22:05
Dr. Amir Horowitz presented preclinical data on Purple Biotech's IM1240, a tri-specific antibody from the CAPTN-3 platform, highlighting its potent anti-tumor activity in treatment-resistant cancers. IM1240 targets 5T4, engaging T and NK cells while blocking NKG2A-mediated immune suppression. Its CD3 capping technology restricts activation to the tumor microenvironment, reducing systemic cytokine release and improving safety. Preclinical studies ...
11-20 14:00
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(2.88) by 79.17 percent. This is a 79.02 percent increase over losses of $(2.86) per share from the same period last year.
11-17 21:05
Oral presentation: November 20, 2026 at 15:00 CET REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity whil...
10-29 21:02
Purple Biotech's IM1240, a tri-specific antibody from its CAPTN-3 platform, has been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 20, 2026. The presentation will highlight IM1240's multi-arm mechanism, NKG2A engagement, pharmacokinetics, and safety in treatment-resistant tumor models. Purple Biotech aims to advance IM1240 toward clinical trials in 2027, pending regulatory approval. The presentati...
10-29 13:00
Purple Biotech Ltd. (NASDAQ:PPBT) stock is surging on Wednesday following a favorable U.S. patent update. The U.S. Patent and Trademark Office granted the biotechnology company a Notice of Allowance regarding a crucial patent application that covers its tri-specific antibody constructs and their spe...
09-02 21:24
Purple Biotech stock surged higher on Wednesday after the company announced a p...
09-02 21:22
Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced that the U.S. Patent and Trademark Office (USPTO) has issued ...
09-02 19:32
今日重点评级关注:康托·菲茨杰拉德:维持InflaRx"超配"评级,目标价从4美元升至6美元;RBC Capital:维持Nuvation Bio"跑赢大市"评级,目标价从19美元升至20美元
08-10 19:24
HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target from $30 to $17.
08-08 02:10